Palavras-chave
Como Citar
Resumo
Prostate cancer (PC) is reported as an important neoplasm worldwide, caused by the uncontrolled multiplication of cells in the prostate. The main risk factors are age over 50 years, family history, genetic susceptibility, hormonal disorders, obesity and environmental factors. Active surveillance of low-risk PC defers aggressive treatment until disease progression and is an increasingly recommended treatment strategy. This strategy aims to reduce costs and decrease treatment-related morbidity without affecting survival. Medicinal Biomagnetism (BM) is based on the distortion of the limit of homeostasis towards hyperacidity and hyperalkalinity of two specific points for each pathogenic microorganism or glandular dysfunction. The induction of loads that are in a vibrational and energetic relationship, by means of medium intensity magnets, greater than 1000 Gauss, corrects or prevents the distortion of the pH of the organs or tissues of the human body. In this way, the neutralization of pathogenic bioenergetic distortions promotes health. The aim of this study was to evaluate the effect of BM in the treatment of prostatic adenocarcinoma, prognostic group 1. After three sessions of BM, the levels of prostate-specific antigen (PSA) decreased and the prostate adenocarcinoma regressed to discrete chronic inflammation. This study represents the first in the evaluation of BM for the treatment of CP and may stimulate further studies in this field that are likely to yield important discoveries.
Referências
AMERICAN CANCER SOCIETY. Cancer Statistics Center, 2021. Disponível em: <https://cancerstatisticscenter.cancer.org/?_7.930736393.1633479858-1872598315.1633479850#!/>. Acesso em: 5 out. 2021a.
AMERICAN CANCER SOCIETY. Key Statistics for Prostate Cancer. Disponível em: <https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html>. Acesso em: 5 out. 2021b.
BERRO, Tala; BARRETT, Elizabeth; ALDUBAYAN, Saud H. Clinical multigene testing for prostate cancer. The Urologic Clinics of North America, v. 48, n. 3, p. 297-309, 2021.
BHANJI, Yasin; ISAACS, William B.; XU, Jianfeng; COONEY, Kathleen A. Prostate Cancer Predisposition. Urologic Clinics of North America, v. 48, n. 3, 283-296, 2021.
BRASIL. Ministério da Saúde. Secretaria de Assistência à Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: Câncer de Próstata. Rio de Janeiro: INCA, 12 mai. 2020. Disponível em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-prostata>. Acesso em 06 out. 2021.
BRASIL. Ministério da Saúde. Secretaria de Assistência à Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Tipos de Câncer: Câncer de Próstata. Rio de Janeiro: INCA, 24 ago. 2021. Disponível em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-prostata>. Acesso em 06 out. 2021.
BROERINGMEYER, Richard; BROERINGMEYER, Mary. Energy Therapy Training Manual. Biohealth Enterprices Inc. USA, 1987.
BOSSA, Adriane Viapiana. Guia Prático dos Pares Biomagnéticos: Biomagnetismo e Terapia Magnética. Cascavel: Par Magnético, 96 p., 2017.
BOSSA, Adriane Viapiana. Descrição dos Pares Biomagnéticos: Biomagnetismo e Bioenergética. 4. ed. Cascavel: Par Magnético, 114 p., 2021a.
BOSSA, Adriane Viapiana. Biomagnetismo Medicinal Avançado, Bioenergética e Desbloqueio Emocional Magnético Avançados. 2. ed. Cascavel: Par Magnético, 281 p., 2021b.
CEDEIRA, Francisco; MONTES DE OCA, Luis Fernando; MARTÍNEZ PAGANO, Emanel. Impacto del cáncer de próstata en el sistema nervioso: dos casos diferentes y revisión de la literatura. Archivos Españoles de Urología, v. 74, n. 7, p. 715-719, 2021.
COMPÉRAT, Eva; VARINOT, Justine; SRIGLEY, John R. Lésions bénignes mimant le cancer de la prostate. Challenges diagnostiques: Benign mimickers of the prostate cancer. Diagnostic challenges. Annales de Pathologie, v. 33, n. 4, p. 237-46, 2013.
CONTI, David V.; DARST, Burcu F.; MOSS, L.C. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, v. 53, n. 1, p. 65-75, 2021.
CORNFORD, Philip; VAN DEN BERGH, Roderick C. N.; BRIERS, Erik; VAN DEN BROECK, Thomas et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, v. 79, n. 2, p. 263-282, 2021.
DAMYANOV, Christo; MASLEV, Ivan; PAVLOV, Vladimir; TODOROV, Alexander. A new treatment method of Advanced Metastatic Tumors. Annals of Clinical Case Reports. v. 4, n. 1647, p. 1-6, 2019a.
DAMYANOV, Christo; MASLEV, Ivan; PAVLOV, Vladimir; TODOROV, Alexander. Integrative oncology at the clinicist’s look chronology for the creation and development of the IPT & BMP Method for treatment of oncological diseases. Clinics in Oncology, v. 4, n. 1671, p. 1-5, 2019b.
EPSTEIN, Jonathan. I.; EGEVAD, Lars; AMIN, Mahul B.; DELAHUNT, Brett; SRIGLEY, John R.; HUMPHREY, Peter A. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The American Journal of Surgical Pathology, v. 40, n. 2, 2016.
FLÔR, Eduardo Clementino Cruz; NOCE, Beatriz Perdigao; ALVES, Thalles Araujo; FERNANDES, Walisson Viana. Risk factors for prostate cancer and the importance of physical exercise as apreventive factor as part of treatment for prostate cancer survivors. Brazilian Journal of Health Review, Curitiba, v.4, n.3, p. 14265-14274, 2021.
FRANK, Bryan L. Biomagnetic Pair Therapy and typhoid fever: a pilot study. Medical Acupuncture, v. 29, n. 5, p. 308-312, 2017.
GOIZ DURÁN, Isaac. El Par Biomagnético. 5. ed. Chapingo, México D. F.: Universidad Autónoma Chapingo, 171 p., 2008.
GOIZ DURÁN, Isaac. Fisiopatología bioenergética. México City, México: Medicinas Alternativas y Rehabilitación S. A. de CV, 362p., 2014.
GOIZ DURÁN, Isaac; MENDOZA CASTELÁN, Guillermo; MENDOZA CASTELÁN, Pedro. Par Biomagnético, Biomagnetismo Médico Y Bioenergética, experiencias de curación, año 2005, tomo II. Chapingo, México D. F.: Universidad Autónoma Chapingo, 2005b.
GOIZ MARTÍNEZ, David. Manual del biomagnetista. Ciudad de México: Biomagnetism Research Institute, 169 p., 2018.
GOIZ MARTÍNEZ, David. Protocolos de Biomagnetismo. Ciudad de México: Biomagnetism Research Institute, 2019.
GORDETSKY, Jennifer; EPSTEIN, Jonathan. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic Pathology, v. 11, n. 25, p. 1-8, 2016.
IARC. International Agency for Research in Cancer. World Health Organization. Prostate Cancer. The Global Cancer Observatory – Globocan, Lyon, France, 2020a. Disponível em: < https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf>. Acesso em 04 out. 2021a.
IARC. International Agency for Research in Cancer. World Health Organization. Brazil. The Global Cancer Observatory – Globocan, Lyon, France, 2020b. Disponível em: < https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf>. Acesso em 04 out. 2021b.
JAVIER-DESLOGES, Juan; MCKAY, Rana R.; SWAFFORD, Austin D.; SEPICH-POORE, Gregory D.; KNIGHT, Rob; PARSONS, J. Kellog. The microbiome and prostate cancer. Prostate Cancer and Prostatic Diseases, 2021.
KAWASE, Makoto; TAKEUCHI, Shinichi; ISHIDA, Takashi; KATO, Seiichi; UNO, Masahiro; KUROKAWA, Kei; TSUZUKI, Toyonori. A case of mucinous adenocarcinoma extending to bladder neck and prostate. Hinyokika Kiyo, v. 67, n. 8, p. 395-398, 2021.
KENSLER, Kevin H.; REBBECK, Timothy. R. Cancer Progress and Priorities: Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research Journals, v. 29, n. 2, p. 267-277, 2020.
KETO, Christopher J.; ARONSON, William J.; TERRIS, Martha K.; PRESTI, Joseph C.; KANE, Christopher J; AMLING, Christopher L.; FREEDLAND, Stephen J. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU International, v. 110, n. 4, p. 492-8, 2012.
LARDAS, Michael; LIEW, Matthew; VAN DEN BERGH, Roderick C.; DE SANTIS, Maria; BELLMUNT, Joaquim; VAN DEN BROECK, Thomas et al. Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review. European Urology, v. 72, n. 6, p. 869-885, 2017.
LEITZMANN, Michael F.; ROHRMANN, Sabine. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clinical Epidemiology, v. 4, p. 1-11, 2012.
MAGNANI, Christopher J.; BIEVRE, Nicolas; BAKER, Laurence C.; BROOKS, James D.; BLAYNEY, Douglas W.; HERNANDEZ-BOUSSARD, Tina. Real-world evidence to estimate prostate cancer costs for first-line treatment or active surveillance. European Urology Open Science, v. 23, p. 20-29, 2021.
MOGHADAM, Solmaz Ohadian; MOMENI, Seyed Ali. Human microbiome and prostate cancer development: current insights into the prevention and treatment. Frontiers of Medicine, v. 15, n. 1, p. 11-32, 2020.
PORTER, Corey M.; SHRESTHA, Eva; PEIFFER, Lauren B.; SFANOS, Karen S. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer and Prostatic Diseases, v. 21, n. 3, p. 345-354, 2018.
PREISSER, Felix; CHUN, Felix K.-. H.; BANEK, Severine; WENZEL, Mike; GRAEFEN, Markus; STEUBER, Thomas; TILKI, Derya; MANDEL, Philipp. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate International, v. 9, n. 3, 113-118, 2021.
REBELLO, Richard J.; OING, Christoph; KNUDSEN, Karen E.; LOEB, Stacy; JOHNSON. David C.; REITER, Robert E.; GILLESSEN, Silke; VAN DER KWAST, Theodorus; BRISTOW, Robert G. Prostate cancer. Nature Reviews, Disease Primers, v. 7, n. 1, 2021.
SILVA, Evellyn Samila Paula da; SOUSA, Isac Gabriel Lopes; ARRUDA, Rejanne Lima. Estudo do tempo entre o diagnóstico e início do tratamento do Câncer de Próstata entre os anos de 2018 a 2020 em um hospital de referência em Araguaína – TO. JNT- Facit Business and Technology Journal, v. 1, n. 28, p. 164-76, 2021.
VIRGO, Katherine S.; RUMBLE, R. Bryan; DE WIT, Ronald; MENDELSON, David S.; SMITH, Thomas J.; TAPLIN Mary-Ellen; WADE III, James L.; BENNETT, Charles L.; SCHER, Howard I.; NGUYEN, Paul L.; GLEAVE, Martin; MORGAN, Scott C.; LOBLAW, Andrew; SACHDEV, Sean; GRAHAM, David L.; VAPIWALA, Neha; SION, Amy M.; SIMONS, Virgil, H.; TALCOTT, James. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. Journal of Clinical Oncology, v. 39, n. 11, p. 1274-1305, 2021.
YOO, Sunghwan; GUJRATHI, Isha; HAIDER, Masoom; KHALVATI, Farzad A. Prostate Cancer detection using deep convolutional neural networks. Scientific Reports, v. 9, n. 19518, p. 1-10, 2019.
WULCZYN, Ellery; NAGPAL, Kunal; SYMONDS, Matthew et al. Predicting prostate cancer specific-mortality with artificial intelligence-based Gleason grading. Communications Medicine, v. 1, n. 10, p. 1-8, 2021.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Angela Mara Rambo Martini, Luciane Neris Cazella, Yuri Martini, Adriane Viapiana Bossa, Jefferson Souza Santos